Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score
Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score
复制标题
DOI：
10.1016/j.healun.2014.02.011
复制
发表时间：
2014-07-01
影响因子：
8.9
通讯作者：
Jorde, Ulrich P.
中科院分区：
文献类型：
--
作者：
Thomas, Sunu S.;Nahumi, Nadav;Jorde, Ulrich P.
背景：左心室辅助装置（LVAD）治疗的生存率取决于适当的患者选择。HeartMate II风险评分（HMRS）是最近推导并验证的，可预测使用连续流LVAD的临床试验患者的90天死亡率。本研究的目的是测试HMRS的有效性预测生存在我们institution.METHODS：我们进行了一项回顾性分析的患者植入HeartMate II（HMII; Thoratec，普莱森顿，CA）LVAD从2004年3月31日至2012年9月20日在哥伦比亚大学医学中心（CMEC）。根据HMRS谱对患者进行分层（HMRS低< 1.58，1.58
BACKGROUND: Survival with left ventricular assist device (LVAD) therapy is dependent on appropriate patient selection. The HeartMate II risk score (HMRS) was recently derived and validated to predict 90-day mortality in clinical trial patients with continuous-flow LVADs. The aim of this study was to test HMRS validity in predicting survival at our institution.METHODS: We performed a retrospective analysis of patients implanted with HeartMate II (HMII; Thoratec, Pleasanton, CA) LVADs from March 31, 2004 to September 20, 2012 at the Columbia University Medical Center (CUMC). Patients were stratified according to HMRS profiles (HMRS Low < 1.58, 1.58